PhotonMD Inc. announced positive results of a clinical trial assessing REVIAN RED, an all-LED cap for the treatment of androgenic alopecia vs. a series of other hair growth devices.
In the randomized, double-blind, placebo-controlled trial, REVIAN RED demonstrated the ability to stop hair loss and subsequently grow new hair, according to a press release.
Adult patients diagnosed with androgenetic alopecia were randomly assigned to a light-based hair growth treatment or placebo cap with no light therapy for 10 minutes per day of use for up to 26 weeks. Participants agreed to cease using all other hair growth products or treatments during the study period.
Target area hair count defined the primary endpoint in both participant groups at week 16. Hair counts were obtained via computer-assisted scans of digital photographs of a defined target area of 1 cm2 centered on a tattoo located in the anterior mid area of the scalp, according to the release.